Resmetirom Poised to Become First NASH Treatment
(MedPage Today) -- Groundbreaking results from a phase III trial have set the stage for resmetirom to become the first drug approved for patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis.
In the so-called MAESTRO-NASH study...
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | International Medicine & Public Health | Liver | Study | Urology & Nephrology